Sponsors of COVID-19 vaccines in development are encouraged to meet with the US Food & Drug Administration “as early as they would like” to start designing Phase II/III trials, Center for Biologics Evaluation & Research Director Peter Marks said in an 21 April podcast interview with Prevision Policy. (See link at the end of the story for the full audio.)
At last count, there are approximately 70 vaccines in development against the SARS-CoV-2 virus. Three are in Phase I –...







